Testing a new drug for advanced melanoma that has spread or cannot be removed

Plain-English translation of NCT06359860 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new drug called ST-1898 to see if it can help people with advanced melanoma — a serious type of skin cancer that has either spread to other parts of the body or cannot be surgically removed. The medication works by blocking multiple pathways that allow cancer cells to grow. Researchers want to find the right dose and understand how well and safely this treatment works.

Advanced melanoma is difficult to treat, and many patients need new options when standard treatments stop working. This medication targets several different growth pathways in cancer cells, which might make it more effective than existing treatments.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with advanced melanoma (stage III or IV) that either cannot be removed by surgery or has spread, and it has progressed despite previous treatment
you are in good enough health to carry out daily activities with minimal assistance (ECOG performance status of 0 or 1)
you have at least one measurable tumor that can be tracked on imaging scans
you have adequate organ function, including normal blood counts, kidney function, and liver function within acceptable ranges
you are willing to provide a tumor tissue sample (either from your medical records or a new biopsy) for testing

You likely don't qualify if…

you have received cancer treatment (chemotherapy, radiation, immunotherapy, or other targeted drugs) within the past 2–4 weeks
you have a serious heart condition, including irregular heartbeat, recent heart attack or stroke, or abnormal heart electrical patterns
you have significant eye problems, including severe vision loss that your doctor believes would make participation unsafe
you are currently pregnant, breastfeeding, or unwilling to use effective contraception during the study and for 3 months afterward
you have had major surgery or significant injury within the past 4 weeks (except for tumor biopsies)

What participation looks like

The trial has two phases. In the first phase, participants will take a daily pill by mouth, starting at a low dose that may be gradually increased to find the safest and most effective dose. In the second phase, a larger group will take the medication at the dose determined to work best. You will have regular visits with your doctor to check your blood counts, organ function, and how well the cancer is responding. You will continue taking the medication until your cancer progresses or you experience side effects you cannot tolerate.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Cancer Hospital & Institute, Beijing